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Background/aims To report the outcome of primary
radiotherapy in patients with progressive optic nerve
sheath meningioma (ONSM).
Methods Theclinicalrecordsofallpatientswerereviewed
in a retrospective, observational, multicentre study.
Results Thirty-four consecutive patients were included.
Twenty-six women and eight men received conventional
or stereotactic fractionated radiotherapy, and were
followed for a median 58 (range 51e156) months.
Fourteen eyes (41%) showed improved visual acuity of
at least two lines on the Snellen chart. In 17 (50%)
eyes, the vision stabilised, while deterioration was
noted in three eyes (9%). The visual outcome was not
associated with age at the time of radiotherapy
(p¼0.83), sex (p¼0.43), visual acuity at the time
of presentation (p¼0.22) or type of radiotherapy
(p¼0.35). Optic disc swelling was associated
with improved visual acuity (p<0.01) and 4/11
patients with optic atrophy also showed improvement.
Long-term complications were dry eyes in ﬁve patients,
cataracts in three, and mild radiation retinopathy in four.
Conclusion Primary radiotherapy for patients with
ONSM is associated with long-term improvement of
visual acuity and few adverse effects.
INTRODUCTION
Optic nerve sheath menigiomas (ONSM) originate
from meningothelial cap cells of arachnoid villi
inside the optic nerve. Whilst being slow-growing
tumours, they are associated with gradual visual
deterioration. Radiotherapy has been reported to
prevent further disease progression and even result
in improved visual acuity in 25e80% of the irradi-
ated eyes.
1e10 By contrast, surgical resection leads
to signiﬁcant or complete loss of any remaining
vision.
1e3 However, the majority of studies
assessing radiotherapy have reported only short-
term results in small numbers of patients.
This multicentre study evaluated the clinical
characteristics and especially the visual outcome, in
34 patients undergoing primary radiotherapy to
treat ONSM. Patterns of visual change, radio-
therapy efﬁcacy, complications and prognostic
factors were assessed. This is believed to be the
largest reported series to date.
MATERIALS AND METHODS
Patients
Thirty-four patients with a diagnosis of ONSM
were treated primarily with radiotherapy between
1998 and 2008 at the orbital centres of the
University of Amsterdam (n¼12), University of
British Columbia (n¼10), University of Adelaide
(n¼8), and the Universities of Utrecht/Rotterdam
(n¼4). Inclusion criteria were a diagnosis of ONSM
based on clinical and imaging evidence or histopa-
thology (n¼9). Exclusion criteria were any surgical
intervention other than biopsy, or no light percep-
tion by the involved eye before treatment.
Radiotherapy
Radiotherapy was offered as the primary treatment
for ONSM in patients with progressive visual
deterioration or visual ﬁeld constriction. In
Amsterdam and Vancouver, radiotherapy was
offered only when the visual acuity was less than
20/40. In the other two centres eight patients
underwent radiotherapy with visual acuities of
more than 20/30.
Radiotherapy was mostly conventional (n¼22),
although stereotactic fractionated conformal
radiotherapy (n¼12) was used for smaller, well-
deﬁned ONSM.
The follow-up was uniform in all clinics at
intervals of 6 weeks, 3 months and 6 months, and
then annually. All patients underwent annual MRI.
Measurements
Retrospective data were collected at presentation,
before radiotherapy and at all follow-up examina-
tions, and included visual acuity, colour vision and
visual ﬁelds, pupil examination, fundoscopy (with
a detailed description of the optic disc combined
with fundus photographs) and Hertel exophthal-
mometer measurements. Ocular motility was
examined at presentation, before and at least once
after radiotherapy. On neuroimaging, the location,
conﬁguration, extension and calciﬁcation before
radiotherapy were documented, with the addition
of progression and extension after radiotherapy.
Deﬁnitions
Dry eyes
All patients underwent a Schirmer test with signs
of corneal dryness classiﬁed as: no corneal changes;
corneal stippling limited to the inferior periphery;
stippling more extended; ulceration; and clouding.
Cataract
Cataract was deﬁned according to the Lens Opacity
Classiﬁcation System II (LOCS II) criteria. The
classiﬁcation system consists of four classes: nuclear
colour, nuclear opalescence, cortical grading and
posterior subcapsular (PSC). A lens was considered
clear if the LOCS II classiﬁcation rated maximal
nuclearcolouras0to1,nuclearopalescenceas0to1,
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registered, cataract was diagnosed. Patients who had undergone
cataract surgery were not staged using the LOCS II system but
were classiﬁed as suffering from cataract.
11 12
Possible retinopathy
The deﬁnition of possible retinopathy was the presence of at
least one haemorrhage or microaneurysm on standardised 508
red-free, black and white retina photographs. We used 508 non-
stereo, red-free photography, a technique slightly modiﬁed from
that described and evaluated by the Eurodiabetes Study.
11 13 In
patients with a follow-up longer than 3 years, fundus ﬂuorescein
angiography was performed.
Visual improvement
Visual improvement was deﬁned as improvement of at least two
lines on the Snellen chart.
Statistical analysis
The results of the study were analysed using the SPSS statistical
software package (version 14.0.2). Differences in baseline data
between groups were compared with independent t tests for
numerical data and Fisher’s exact test for categorical data.
Variables with p<0.1 were entered in a multivariate analysis,
using logistic regression analysis. R statistical software (version
2.5.1) was used to analyse longitudinal patterns. Prognostic
factors for improvement in visual acuity were analysed using
a linear random effect model. If bilateral ONSM was present,
the data were analysed for the ﬁrst affected eye.
RESULTS
Sex distribution
There were 26 female and eight male patients. The mean age at
onset was 44.9 (range 12e66) years and was 49.45 (range
29e69) years at the beginning of radiotherapy.
Follow-up
The mean total follow-up time was 110.8 (range 58e235, median
84) months. The mean follow-up time after radiotherapy treat-
ment was 58.32 (range 51e156, median 55) months.
Symptoms and signs
All 34 patients presented with visual deterioration, among
which 21 cases had a chronic onset (measured in months), 12
had a sub-acute onset (weeks) and only one had an acute onset
(days). Transient visual obscuration was noted in ﬁve patients,
18 had evidence of proptosis, and diplopia was present in six
patients. Eight patients presented with retrobulbar pain. Optic
disc swelling was noted in 20 patients, optic atrophy in 11, optic
swelling with segmental atrophy in one, and two patients
showed no abnormalities (table 1).
Imaging
In 22 patients, the ONSM involved the full length of the optic
nerve; in 11, the tumour had a posterior location; in one, the
tumourinvolvedtheanterioraspectoftheopticnerve.Opticcanal
extension was encountered in nine patients, with ﬁve also having
intracranialextension.Nonehadinvolvementoftheopticchiasm.
Histopathology
Histology was available in eight patients: four tumours were
meningothelial and four were transitional, of which one also had
psammoma bodies.
Radiotherapy
Twenty-one patients received 54 Gy in 30 fractions, six received
50.4 Gy in 28 fractions, and 13 received 45 Gy stereotactically in
25 fractions. One patient received simultaneous bilateral radio-
therapy for bilateral involvement.
Visual outcome
The visual acuity at the onset of radiotherapy was between
20/20 or 20/30 in eight patients, 20/40 and 20/80 in 14 patients,
20/100 and 20/200 in eight patients, and between 20/200 and
hand movement (HM) in four patients (table 2).
The visual deterioration characteristics were compared
between follow-up and the period before radiotherapy. Twenty-
one patients showed a chronic pattern of visual deterioration,
12 had sub-acute duration, and only one had an acute onset.
After radiotherapy, 15 patients showed improved visual acuity
of at least two Snellen lines, with 11 of this group improving by
more than three lines. Among those with improvement, all
except one had chronic deterioration of their visual acuity before
treatment. In 17 eyes, the vision stabilised, while deterioration
was noted in three eyes. We found the following patterns of
visual changes during follow-up after radiotherapy:
Early visual improvement
Eleven patients showed signiﬁcant improvement of their visual
acuity (more than three Snellen chart lines) within the ﬁrst few
monthsafterradiotherapy.Visualﬁeldsweresigniﬁcantlyimproved
insevenpatientsandintwopatientswasnoinformationavailable,
while colour vision showed some improvement in ﬁve patients.
All of these patients had optic disc swelling at the time of
radiotherapy and for months afterwards. All of these patients
except one (sub-acute) had chronic onset of visual deterioration.
Two patients in this group after an initial improvement in
a later stadium showed some deterioration of visual acuity. One,
who was a 65-year-old woman with bilateral ONSM and optic
atrophy, underwent only right-sided radiotherapy; despite an
initial improvement in her vision from 20/80 to 20/30 in
2 months, her visual acuity deteriorated to 20/100 over 3 years.
The cause of this secondary deterioration was a PSC cataract
and epiretinal membrane. Another patient showed improvement
of vision from 20/40 to 20/30 within 3 months after
Table 1 Clinical and demographic characteristics of patients ONSM RT




Age at presentation (years, mean6SD) 44.9614
Age at time of RT (months) 49.5
Bilateral 3 (9)
Unilateral 31 (91)
Presenting signs and symptoms
Visual deterioration 34 (100)
Proptosis 18 (53)
Pain/discomfort 6 (18)
Disc oedema 20 (59)
Disc atrophy 12 (35)
Normal disc 2 (6)
Limitations in ocular motility 4 (12)
Visual obscuration 5 (15)
Follow-up (months, mean) 110 (median 84)
Post RT time (months, mean) 58.32 (median 55)
OSNM, optic nerve sheath meningioma; RT, radiotherapy.
Values are n (%) unless state otherwise.
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3 years, but then deteriorated to 20/200, and ﬁnally to counting
ﬁngers (CF) in 8 years as a result of macular degeneration. In this
group, three patients underwent biopsies, with two cases having
meningothelial meningiomas and one case a transitional
meningioma.
Late visual improvement and stabilisation
Three patients showed delayed improvement of their visual
acuity. Two had chronic and one had sub-acute visual deterio-
ration. One patient with a biopsy-proven meningothelial
meningioma underwent radiotherapy when his visual acuity
was 20/200. His visual acuity in the ﬁrst 2 years ﬂuctuated
between 20/200 and 20/400. In the third year, his visual acuity
improved to 20/40 and it then remained stable at that level for
6 years. The visual acuity remained unchanged within the ﬁrst
year in all three patients. Two of these patients had visual acuity
of CF at the time of radiotherapy. Their vision improved in the
second year to 20/80 and 20/200. The third patient improved
from 20/200 to 20/100 in the second year. Neither colour vision
nor visual ﬁelds were improved in these three patients.
No visual improvement and stabilisation
Seventeen patients showed any change in visual acuity, visual
ﬁelds and colour vision during the mean follow-up period of
47 months. After this period, one patient had a marginal visual
deterioration from 20/60 to 20/80 and a minor deterioration of
colour vision. The only complication post-radiotherapy in this
patient was dry eye.
Primary visual deterioration
Three patients showed visual deterioration and constriction of
the visual ﬁelds within weeks of radiotherapy. Biopsies were
performed in all of these patients at three different centres
before radiotherapy. Histopathology showed meningothelial
tumours in two patients and a transitional meningioma in one.
Radiotherapy in these patients consisted of 54 Gy in 1.8-Gy
fractions. The only ocular abnormality at the time of visual
deterioration was optic disc oedema.
Prognostic factors for visual outcome
There was no signiﬁcant association between age at presenta-
tion or the timing of radiotherapy and visual outcome (p¼0.82),
nor was sex (p¼0.43) or the type of radiotherapy a prognostic
factor (p¼0.35). Optic disc atrophy and swelling were the only
statistically signiﬁcant prognostic factors found for visual
outcome. Although optic disc swelling was associated with
a better visual prognosis compared with optic atrophy (p<0.01),
four patients with disc atrophy showed improvement in their
visual acuity. In addition, chronic onset was associated with
a better visual prognosis after radiotherapy, but this was not
statistically signiﬁcant (p¼0.11), nor was visual acuity at the
time of presentation a prognostic factor (p¼0.22).
Risk factors
Hypertension was diagnosed in six patients before treatment. In
two patients, this was combined with diabetes mellitus, and one
had atherosclerosis. The mean follow-up in this group was
51 months post-radiotherapy, and none of these patients
showed any sign of cataract, dry eyes or retinopathy.
Complications
Early complications
Sixteen patients during 6 weeks of radiotherapy showed signs of
temporary erythema around the area of irradiation. In 12
patients, this was associated with temporary hair loss. Six
patients had headaches during radiotherapy; of these patients
four were treated with dexamethasone with good response.
Late complications
Dry eyes were noticed in ﬁve patients: three with sectoral
stippling and two with extended stippling of the cornea. Three
patients showed signs of a PSC cataract 2 years after treatment.
In two patients, no signs of cataract were present before treat-
ment. One patient had a pre-existing nuclear cataract that was
unchanged 3 years after treatment.
Retinopathy
All patients followed for longer than 4 years underwent ﬂuo-
rescein angiography. In six eyes, areas of hyperﬂuorescence
consistent with window defects were noted in the posterior
pole. One patient had a microaneurysm and one had cotton
wool spots at the posterior pole of the retina 4 years after
treatment. In another patient, haemorrhage and microaneurysm
ﬁrst appeared at the posterior pole 3 years after treatment. Both
of these patients were treated using conformal conventional
radiotherapy with 54 Gy in 1.8-Gy fractions. In all of the
patients with retinal changes after radiotherapy, ONSM
involved the full length of the optic nerve (table 3).
Pituitary function
During follow-up, no signs or symptoms attributable to
impaired pituitary function were noted. Detailed endocrinolog-
ical testing is beyond the scope of this report, which focuses on
visual outcome.
DISCUSSION
In the past 30 years, there have been several reports on the
treatment of ONSM with radiotherapy.
1e10 However, none of
these studies were randomised, controlled or prospective, and
few had a follow-up time that was sufﬁciently long for the true
efﬁcacy of irradiation and the incidence of delayed visual
improvement or loss to be noted. However, a controlled, rand-
omised study that compares surgery or observation with
radiotherapy is unlikely to be undertaken.
In a retrospective study, Turbin et al compared 18 patients
who received primary radiotherapy for ONSM with two













VA TX 14 17 3
20/20e20/30 8 1 7 0
20/40e20/80 14 6 6 2
20/100e20/200 8 5 2 1
20/400eHM 4 2 2 0
Optic disc TX
Oedema 21 10 10 1
Atrophy 11 3 6 2








HM, hand movement; RT, radiotherapy; TX, treatment; VA, visual acuity.
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observation. The primary radiotherapy group was the only
group that did not experience visual deterioration, with 44.4%
showing at least two lines of improved visual acuity. A 33%
incidence of radiation-induced toxicity was reported, without
specifying the details.
3
Our 34 patients were treated and assessed in four centres
using comparable protocols, with a mean follow-up of 9 years
and a median of 4 years. In this series, unlike earlier studies, no
blind eyes were included.
Visual outcome and prognostic factors
Seventeen of the 34 patients in our study showed visual stabili-
sation, 14 showed improvement and three had visual deteriora-
tion. Two patients in the improved group showed visual
deterioration 3 and 4 years later because of epiretinal membranes
and cataracts, which were most probably caused by the irradia-
tion. As we reported in an earlier study of 88 patients with
ONSM,among39patientswhowerefollowedbyobservation,24
(71%) had a visual acuity of 20/50 or better after a mean follow-
up of 5.8 years. Fifteen (44%) patients in this group had stable
visionof20/20or20/50.
2However,stabilisationorimprovement
in patients who received radiotherapy (91%) is undeniably
a better result. The presence of disc swelling was associated with
as i g n i ﬁcantly better response, while four of nine patients with
discatrophyshowedsomevisualimprovement.Thiswasalsothe
only signiﬁcant prognostic factor. Chronic onset of visual dete-
rioration was associated with a better response to radiotherapy,
although this was not signiﬁcant.
Complications
Retinopathy developed in three eyes, all after follow-up for more
than 3 years. Turbin et al. reported four cases of retinopathy in
18 patients, although the time span was not stated.
3 Other
studies using only fractionated stereotactic radiotherapy have
also reported retinopathy that appeared between 2 and 4 years
afterwards.
61 41 5Recent studies have shown that in orbital
radiotherapy, diabetes mellitus (DM) and hypertension are risk
factors for the development of retinopathy.
11 Our two patients
with retinopathy did not have DM or hypertension. Four
patients with hypertension and one with hypertension and DM
who received radiotherapy did not show any signs of retinop-
athy after a mean follow-up of 3.5 years.
Conventional versus stereotactic radiotherapy
Twelve patients in our study received stereotactic radiotherapy
and22receivedconformalradiotherapy.Therewasnostatistically
signiﬁcant difference in the visual outcome between the groups.
Of our patients with complications, two with post-radiation
retinopathy, two with cataracts and two with dry eyes were
treated using conformal conventional radiotherapy techniques.
Note that the stereotactic radiotherapy group included smaller
tumoursatagreaterdistancefromtheglobe.Retinopathyhasalso
been reported in patients who have undergone stereotactic
radiotherapy.
3 61 41 5However,onewouldexpectgreaterprecision
with this technique and thus avoidance radiation of vulnerable
healthy tissue.
16 Indeed, a primary concern of radiotherapy is its
late effects on the adjacent brain parenchyma and other tissues.
The risk of radionecrosis of the brain has a threshold of 50e54 Gy
with standard fractions of 1.8e2 Gy per day. Combined data for
irradiationofpituitaryadenomasshowanincidenceofopticnerve
or chiasm injury of 1.5% at a dose of 45e50 Gy in 1.8e2-Gy
fractions.
17e20 Late pituitary dysfunction has become a more
recognised late effect of radiotherapy. However, with proper
modern treatment planning, the pituitary gland can often be
avoidedinpatientswithONSM.Noneofourpatientsshowedany
signs of radionecrosis of the brain or pituitary gland dysfunction.
Conclusion and recommendations
Primary radiotherapy is associated with improvement or stabi-
lisation of visual acuity in the majority of patients with
progressive ONSM. Only a small proportion will progress
despite radiation, and most adverse effects are transient or
minor. Although we individualise the treatment strategy, we
recommend radiotherapy in patients with progressive visual
deterioration and/or visual ﬁeld constriction. Fractionated
stereotactic radiotherapy might be considered for treatment,
particularly for well-deﬁned lesions.
2
Inourstudy,therewasnosigniﬁcantcorrelationbetweenvisual
acuity at the time of treatment and visual outcome after treat-
ment.Ingeneral,imagingisdoneat6-to12-monthintervalsafter
disease activity has been assessed. Our strategy includes reas-
sessment on a 6-month basis with serial neuro-ophthalmological
and visual ﬁeld examinations, unless progressive symptoms or
unusual disease activity dictate more frequent evaluation.
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Late complications
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